Dundar T, Cetinkaya E, Yurtsever I, Uysal O, Aralasmak A
Contrast Media Mol Imaging. 2022; 2022:6948422.
PMID: 35185410
PMC: 8825574.
DOI: 10.1155/2022/6948422.
Mathios D, Srivastava S, Kim T, Bettegowda C, Lim M
Neuromolecular Med. 2021; 24(2):74-87.
PMID: 34297308
DOI: 10.1007/s12017-021-08677-9.
Nakata J, Isohashi K, Oka Y, Nakajima H, Morimoto S, Fujiki F
Diagnostics (Basel). 2021; 11(6).
PMID: 34198874
PMC: 8226723.
DOI: 10.3390/diagnostics11061041.
Zhang J, Liu Q, Yuan Z, Zhao L, Wang X, Wang P
Front Oncol. 2019; 9:257.
PMID: 31032223
PMC: 6473059.
DOI: 10.3389/fonc.2019.00257.
Muto M, Frauenfelder G, Senese R, Zeccolini F, Schena E, Giurazza F
Radiol Med. 2018; 123(7):545-552.
PMID: 29508242
DOI: 10.1007/s11547-018-0866-7.
Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy.
Kleinberg L
Patient Prefer Adherence. 2016; 10:2397-2406.
PMID: 27920506
PMC: 5125766.
DOI: 10.2147/PPA.S93020.
Emerging Techniques in Brain Tumor Imaging: What Radiologists Need to Know.
Kim M, Kim H
Korean J Radiol. 2016; 17(5):598-619.
PMID: 27587949
PMC: 5007387.
DOI: 10.3348/kjr.2016.17.5.598.
MRI during radiotherapy of glioblastoma : Does MRI allow for prognostic stratification?.
Leitzen C, Wilhelm-Buchstab T, Schmeel L, Garbe S, Greschus S, Mudder T
Strahlenther Onkol. 2016; 192(7):481-8.
PMID: 27259515
DOI: 10.1007/s00066-016-0983-y.
Survival kinase genes present prognostic significance in glioblastoma.
Varghese R, Liang Y, Guan T, Franck C, Kelly D, Sheng Z
Oncotarget. 2016; 7(15):20140-51.
PMID: 26956052
PMC: 4991443.
DOI: 10.18632/oncotarget.7917.
Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients.
Yoo R, Choi S
Magn Reson Med Sci. 2016; 15(2):165-77.
PMID: 26726012
PMC: 5600053.
DOI: 10.2463/mrms.rev.2015-0053.
A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression.
Zhang P, Guo Z, Zhang Y, Gao Z, Ji N, Wang D
Proteome Sci. 2015; 13:12.
PMID: 25866482
PMC: 4393599.
DOI: 10.1186/s12953-015-0066-5.
Early Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma.
Surapaneni K, Kennedy B, Yanagihara T, DeLaPaz R, Bruce J
World Neurosurg. 2015; 84(1):163-72.
PMID: 25772608
PMC: 4922637.
DOI: 10.1016/j.wneu.2015.03.008.
Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.
Levin V, Mendelssohn N, Chan J, Stovall M, Peak S, Yee J
J Neurooncol. 2015; 122(1):145-50.
PMID: 25575937
DOI: 10.1007/s11060-014-1693-x.
Experiences and expectations for glioma immunotherapeutic approaches.
Yamanaka R, Hayano A
Front Oncol. 2014; 4:355.
PMID: 25540770
PMC: 4261702.
DOI: 10.3389/fonc.2014.00355.
Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.
Armstrong T, Gilbert M
Curr Treat Options Oncol. 2014; 15(4):519-28.
PMID: 25173554
DOI: 10.1007/s11864-014-0302-8.
Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy.
Kocher M, Wittig A, Piroth M, Treuer H, Seegenschmiedt H, Ruge M
Strahlenther Onkol. 2014; 190(6):521-32.
PMID: 24715242
DOI: 10.1007/s00066-014-0648-7.
Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis.
Cha J, Kim S, Kim H, Kim B, Kim Y, Lee J
AJNR Am J Neuroradiol. 2014; 35(7):1309-17.
PMID: 24676005
PMC: 7966603.
DOI: 10.3174/ajnr.A3876.
Diffusion abnormalities of the corpus callosum in patients receiving bevacizumab for malignant brain tumors: suspected treatment toxicity.
Futterer S, Nemeth A, Grimm S, Ragin A, Chandler J, Muro K
J Neurooncol. 2014; 118(1):147-53.
PMID: 24574050
DOI: 10.1007/s11060-014-1409-2.
True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.
Song Y, Choi S, Park C, Yi K, Lee W, Yun T
Korean J Radiol. 2013; 14(4):662-72.
PMID: 23901325
PMC: 3725362.
DOI: 10.3348/kjr.2013.14.4.662.
Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.
Suh C, Kim H, Choi Y, Kim N, Kim S
AJNR Am J Neuroradiol. 2013; 34(12):2278-86.
PMID: 23828115
PMC: 7965196.
DOI: 10.3174/ajnr.A3634.
